Evaluation of the Impact of Chemotherapy on Body Odor in Adolescents and Young Adults in Oncology
NCT ID: NCT04899505
Last Updated: 2025-05-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
27 participants
OBSERVATIONAL
2021-10-21
2025-05-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessment of Sleep Quality in Patients Treated for Cancer Between 15 and 24 Years of Age
NCT06904495
JUMP Prevalence of Sarcopenia and Chemobrain in Post-cancer Patients
NCT05800535
Quality of Life, Employment, and Informal Care Costs in Women Who Are Receiving Chemotherapy for Breast Cancer
NCT00115505
Impact on Cognitive Function and Quality of Life of Adjuvant Chemotherapy in Patients Aged Over 65 Years: Application to Breast Cancer or Colon
NCT01333735
Improving Treatment-Related Symptom Management in Adolescents and Young Adults With Cancer
NCT04594096
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Evaluation on appearance of unpleasant body odors
Incidence of the development of unpleasant body odors in AYA oncology patients
Evaluation on appearance of unpleasant body odors
Percentage of patients reporting discomfort with unpleasant body odor that occurred during their treatment. This percentage will be calculated from the response to item Q1 of the patient questionnaire during the fourth course of chemotherapy in the AJA oncology department.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Evaluation on appearance of unpleasant body odors
Percentage of patients reporting discomfort with unpleasant body odor that occurred during their treatment. This percentage will be calculated from the response to item Q1 of the patient questionnaire during the fourth course of chemotherapy in the AJA oncology department.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* New patients treated at the Curie Institute and hospitalized in the AJA oncology department;
* Patient undergoing chemotherapy administered intravenously;
* Solid tumors.
Exclusion Criteria
* Persons deprived of their liberty or under guardianship (including guardianship);
* Inability to undergo medical monitoring of the trial for geographical, social or psychological reasons.
15 Years
25 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut Curie
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institut Curie
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IC 2021-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.